Taysha Gene Therapies (TSHA) financial statements
Taysha Gene Therapies reported revenue of $10M in fiscal 2025, up 57.5% a year over 3 years.
Net income was -$109M.
Free cash flow was -$94M.
The diluted share count rose 1710% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Taysha Gene Therapies's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $3M | $15M | $8M | $10M |
| Research and development | $32M | $132M | $91M | $57M | $66M | $86M |
| Selling, general and admin | $11M | $41M | $37M | $30M | $29M | $34M |
| Operating income | -$43M | -$173M | -$162M | -$72M | -$91M | -$110M |
| Interest expense | $28,000 | $1M | $4M | $5M | $102,000 | $63,000 |
| Income tax | $0 | — | $0 | $0 | $0 | $0 |
| Net income | -$60M | -$175M | -$166M | -$112M | -$89M | -$109M |
| EPS (diluted) | -$3.40 | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 |
| Diluted shares | 18M | 38M | 44M | 116M | 250M | 320M |
| Operating margin | — | — | -6492.7% | -468.8% | -1097.6% | -1130.6% |
| Net margin | — | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
Balance sheet
Fiscal years, from Taysha Gene Therapies's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $251M | $149M | $88M | $144M | $139M | $320M |
| Total current assets | $258M | $160M | $96M | $150M | $142M | $325M |
| Property, plant and equipment | $287,000 | $51M | $15M | $11M | $7M | $7M |
| Total assets | $259M | $214M | $126M | $173M | $160M | $343M |
| Total current liabilities | $7M | $52M | $63M | $37M | $26M | $27M |
| Long-term debt | — | $37M | $38M | $41M | $44M | $50M |
| Total liabilities | $8M | $119M | $125M | $98M | $89M | $96M |
| Shareholders' equity | $251M | $95M | $949,000 | $75M | $72M | $247M |
| Net debt | -$251M | -$112M | -$50M | -$103M | -$95M | -$270M |
Cash flow
Fiscal years, from Taysha Gene Therapies's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$31M | -$117M | -$88M | -$73M | -$81M | -$93M |
| Capital spending | $82,000 | $15M | $21M | $4M | $374,000 | $738,000 |
| Free cash flow | -$31M | -$132M | -$109M | -$77M | -$82M | -$94M |
| Stock-based compensation | $3M | $18M | $18M | $8M | $13M | $13M |
| Free cash flow margin | — | — | -4356.9% | -497.6% | -979.2% | -960.1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TSHA.
Open TSHA in InvestinglyQuestions
What was Taysha Gene Therapies's revenue in 2025?
$10M in fiscal 2025, from its 10-K filing.
How much free cash flow does Taysha Gene Therapies generate?
-$94M in fiscal 2025 (operating cash flow minus capital spending).
From Taysha Gene Therapies's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.